NOVAVAX EVENTS

[dothedd]

Events

13th Annual BIO CEO & Investor Conference
New York, NY
February 14-15, 2011
Presenter: Dr. Rahul Singhvi
Webcast: click here.

World Health Organization
7th Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials
Geneva, Switzerland
February 17-18, 2011
Presenter: Dr. Greg Glenn

6th Latin America Clinical Trials Conference
Miami, FL
March 1–2, 2011
Examination of a Clinical Trial Conducted in Mexico City which Enrolled 4,550 Subjects During the Pandemic of 2009 Preventing the Spread of H1N1
Keynote Speaker: Kathy Lenhard

2011 Citi Global Healthcare Conference
New York, NY
March 1–3, 2011
Speaker: Dr. Rahul Singhvi

Roth Growth Stock Conference
Dana Point, CA
March 13 – 16, 2011
Presenter: Dr. Rahul Singhvi
Webcast: click here.

BIT’s Life Science’s Vaccines Congress (WCV 2011): The Future of Global Vaccines
Beijing, China
March 23-25, 2011
Commercialization Strategies for Vaccines in the Emerging Markets
Keynote Speaker: Dr. Rahul Singhvi

4th International Conference on Immunopotentiators in Modern Vaccines (IMV)
Porto, Portugal
April 6 -8, 2011
Presenter: Dr. Greg Glenn

World Vaccine Congress
Washington, DC
April 11-14, 2011
Collaborations and Co-development between Start-up Biotech and Big Pharma
Presenter: Dr. Rahul Singhvi

Skin Vaccination Summit
Washington, DC
October 12-14, 2011
Panel Speaker: Dr. Greg Glenn

[dothedd]

NOVAVAX Announces Conference Call to Discuss Results From Phase I Trial of Respiratory Syncytial Virus Vaccine Candidate

ROCKVILLE, Md., Oct. 10, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will conduct a conference call for invited analysts and institutional investors on October 13, 2011 at 10:30 am ET to review the recent top-line results from a Phase I clinical trial of its respiratory syncytial virus (RSV) fusion (F) recombinant nanoparticle vaccine candidate. Participating on the call will be Gregory M. Glenn, M.D., Senior Vice President and Chief Medical Officer of Novavax, and Pedro A. Piedra, M.D., Professor at Baylor College of Medicine in the Department of Molecular Virology and Microbiology. They will review recent safety, immunogenicity and tolerability findings from the study which were presented at the 5th Vaccine and ISV Annual Global Conference in Seattle earlier this week.

Conference Call Information

The conference call will be accessible on Novavax's website at www.novavax.com under the "Investor Info/Events" tab or by telephone at 1 [phone] (domestic) or 1 [phone] (international). A replay of the webcast will be available on the Novavax website for 90 days after the call and a replay of the conference call will be available following the call. To access the replay of the conference call, dial 1 [phone] (domestic) or 1 [phone] (international) and enter pass code 17801248.

About Respiratory Syncytial Virus

RSV is the most important viral cause of lower respiratory tract infection in infants and children worldwide. The global disease burden is estimated at 64 million cases and 160,000 deaths every year. RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in the United States. Each year, 90,000 to 147,000 children in this age group are hospitalized due to RSV infection. Almost all children will have had an RSV infection by their second birthday. When infants and children are exposed to RSV for the first time, 25% to 40% of them have signs or symptoms of bronchiolitis or pneumonia, and 0.5% to 2% will require hospitalization. Most children hospitalized for RSV infection are under 6 months of age. Additionally, wheezing illnesses caused by RSV, particularly those severe enough to lead to hospitalization, are associated with an increased risk of asthma at school age.

It is also estimated that more than 8.5 million adults, including the elderly over age 65 years, are infected and 900,000 patients are hospitalized annually due to RSV infection in the United States and major European countries. In the United States alone there are 177,500 hospitalizations among high-risk adults resulting in annual medical costs exceeding $1 billion. There is currently no approved vaccine for the prevention of RSV.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Using innovative virus-like particle (VLP) and recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces potent vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India and LG Life Sciences of Korea. Together, these companies have worldwide commercialization capacity and the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's website: www.novavax.com.

CONTACT: Frederick W. Driscoll
VP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000

Source: Novavax, Inc.